Emily Hyle is a Clinician-Investigator in the Division of Infectious Diseases at the Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School. As a member of the Cost-effectiveness of Preventing AIDS Complications (CEPAC) research team, her research focuses on using simulation modelling & cost-effectiveness analysis to investigate clinical and public health interventions for people with HIV. Funded by the National Institutes of Health (NIH), Emily has led & contributed to model-based analyses that include studies on HIV and non-communicable comorbidities, HIV drug resistance, laboratory monitoring, point-of-care testing and loss to follow up. Her research is cited in the US Department for Health and Human Services Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, as well as the World Health Organization (WHO) Consolidated guidelines on the use of antiretroviral drugs for treating & preventing HIV infection.